Allogene Therapeutics
(NASDAQ) ALLO
Allogene Therapeutics Financials at a Glance
Market Cap
$711.02M
Revenue (TTM)
$0.00
Net Income (TTM)
-$173.76M
EPS (TTM)
-$0.77
P/E Ratio
-2.68
Dividend
$0.00
Beta (Volatility)
1.69 (High)
Dividend
$0.00
Beta (Volatility)
1.69 (High)
Price
$2.13
Volume
25,919,246.963
Open
$2.02
Price
$2.13
Volume
25,919,246.963
Open
$2.02
Previous Close
$2.13
Daily Range
$2.02 - $2.19
52-Week Range
$0.98 - $4.46
Estimated Earnings Date
Aug 12, 2026
Dividend
$0.00
Beta (Volatility)
1.69 (High)
Price
$2.13
Volume
25,919,246.963
Open
$2.02
Previous Close
$2.13
Daily Range
$2.02 - $2.19
52-Week Range
$0.98 - $4.46
Estimated Earnings Date
Aug 12, 2026
ALLO News
ALLO: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Allogene Therapeutics
Industry
Biotechnology
Sector
Health CareEmployees
152
CEO
David D. Chang, MD, PhD
Website
www.allogene.comHeadquarters
South San Francisco, CA 94080, US
ALLO Financials
Key Financial Metrics (TTM)
Gross Margin
0.00%
Operating Margin
0.00%
Net Income Margin
0.00%
Return on Equity
-56.45%
Return on Capital
-55.07%
Return on Assets
-43.88%
Earnings Yield
-37.31%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$711.02M
Shares Outstanding
345.15M
Volume
25.92M
Avg. Volume
10.34M
Financials (TTM)
Gross Profit
-$77.25M
Operating Income
-$190.22M
EBITDA
-$160.41M
Operating Cash Flow
-$109.23M
Capital Expenditure
-$296.00K
Free Cash Flow
-$109.53M
Cash & ST Invst.
$266.89M
Total Debt
$81.05M
Allogene Therapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$0.00
N/A
Gross Profit
-$2.87M
+7.4%
Gross Margin
0.00%
N/A
Market Cap
$711.02M
N/A
Market Cap/Employee
$3.15M
N/A
Employees
226
N/A
Net Income
-$42.61M
+28.7%
EBITDA
-$39.44M
+30.2%
Quarterly Fundamentals
Total Cash
$266.89M
-4.7%
Total Debt
$81.05M
-0.3%
Accounts Receivable
$1.30M
N/A
Inventory
$0.00
N/A
Long Term Debt
$72.63M
-10.7%
Short Term Debt
$8.42M
N/A
Return on Assets
-43.88%
N/A
Return on Invested Capital
-51.74%
N/A
Free Cash Flow
-$12.92M
+75.6%
Operating Cash Flow
-$12.91M
+75.6%